**West Yorkshire Guideline for the Management of Chronic kidney Disease (CKD) for Adults**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Think  **C**ardiovascular | | | | Think  **K**idneys | | | Think  **D**iabetes | | |
|  | | | |  | |  | | | |
| **What is CKD?**  CKD is the presence of one of the following for>3 months | | | | |  | Offer Screening for CKD using eGFR, serum creatinine and Urine Albumin: Creatinine Ratio (UACR) to people with any of the following risk factors:   * All people living with diabetes at least annually * For those with an eGFR<60ml/min/1.73m2 a UACR should be requested * Hypertension–annually as part of hypertensions reviews [https://cks.nice.org.uk/topics/hypertension/diagnosis/investigations/](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fcks.nice.org.uk%2Ftopics%2Fhypertension%2Fdiagnosis%2Finvestigations%2F&data=05%7C01%7Channah.beba%40nhs.net%7C9eb24a76dfe448a143a908dbccd1649c%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638328971922417624%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=WJe2wMIjXzK0rU%2F1%2FerKlvKheLeWsKmg7oK%2BYk3zzr0%3D&reserved=0) * Cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral arterial disease or cerebral vascular disease) annually as part of routine reviews * History of acute kidney injury (monitor yearly for 3 years even if function back to baseline) * Structural renal tract disease, recurrent renal calculi or prostatic hypertrophy * Multi-system disease e.g., Systemic lupus erythematosus, vasculitis, myeloma * Family history of end-stage kidney disease (GFR category G5) or hereditary kidney disease * Haematuria /Proteinuria (opportunistic detection) * Treated with nephron-toxic agents (NSAIDs, Lithium, Calcineurin inhibitors, Aminosalicylates etc) | | | |
| Markers of Kidney Damage (one or more) | | | * Albuminuria (UACR ≥3 mg/mmol) confirmed on an early morning urine sample if UACR <70mg/mmol. * Urine sediment abnormalities e.g., presence of red (could indicate glomerular disease) or white blood cells (could indicate interstitial nephritis or infection e.g. pyelonephritis) , tubular epithelial cells (could indicate parenchymal disease) * Electrolyte and other abnormalities due to tubular disorders * Abnormalities detected by histology. * Structural abnormalities detected by imaging. * History of kidney transplantation | |  |
| Decrease eGFR | | | eGFR of <60 ml/min/1.73 m2 (eGFR categories G3a–G5) | |  |
| Every patient at the time of a clinician diagnosing CKD should have a urine dipstick because haematuria raises possibility of systemic renal disease or structural renal abnormalities which needs further assessment.  Haematuria   1. Use dipstick reagent strips rather than urine microscopy. 2. Evaluate further if a result of 1+ or more (initially repeat dipstick in 2 weeks) 3. Result is not useful if the person is menstruating if someone has a catheter or has a known infection. |  | Urine Albumin: Creatinine Ratio (UACR) and CKD Diagnosis  UACR is a useful marker of renal damage and complication risk. It is the usual method of assessing proteinuria. A confirmed (repeated) UACR>3mg/mmol represents proteinuria which is clinically significant.  CKD diagnosis – inform patient, signpost to patient resources, check eGFR if not already done and add coding for CKD (detailed G#A#). Manage CKD as per guideline and make referrals as needed.  Check eGFR and if <60ml/min/1.73m2 or <90 ml/min/1.73m2  and other markers of kidney damage  UACR 3-70mg/mmol  (Confirm with subsequent early morning sample)  UACR>70mg/mmol  (No need to repeat the sample)  eGFR>60ml/min/1.73m2  Continue to screen as recommended by co-morbidities.  UACR<3mg/mmol | | | | | |  | KFRE (Kidney Failure Risk Equation)  [The Kidney Failure Risk Equation](https://kidneyfailurerisk.co.uk/)    Healthcare professionals can use the Kidney failure risk equation to determine 2 and 5 year risk of treated kidney failure (dialysis and transplantation) for a patient with CKD stage 3a-5  There are also videos available on this website to explain risk to people living with CKD [www.kidneyfailurerisk.co.uk](http://www.kidneyfailurerisk.co.uk)  NB: KFRE must be calculated using eGFR EPI (not MDRD) |

**How do we categorise CKD, how often should we test and when should we refer/seek advice?**

When reviewing results, place the test results in clinical context including consideration of why the blood tests were taken.  If history of acute illness, then assess and manage accordingly. Consider acute kidney injury (AKI) and the possibility of obstruction if rapidly declining eGFR. Think Kidneys <https://www.thinkkidneys.nhs.uk/aki/resources/primary-care/>, [https://www.thinkkidneys.nhs.uk/campaign/](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.thinkkidneys.nhs.uk%2Fcampaign%2F&data=05%7C01%7Channah.beba%40nhs.net%7C9eb24a76dfe448a143a908dbccd1649c%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638328971922573838%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=EZ218FXxUZ5zbgI5RHACBvIf8IHV2aQyHumDmvBUgsg%3D&reserved=0)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Frequency of Monitoring  (***number of times per year shown in table as italicised number****)* | | | | Urinary Albumin Creatinine Ratio (UACR) | | |  | **WHEN TO REFER**  **Where referral required, this should be to renal services if the patient does not have diabetes, or to combined diabetes/renal clinic for patient with diabetes (unless suspected or known non-diabetic kidney disease or eGFR <20ml/min1.73 m2 in which case referral should be to renal service)**  [[**Refer adults with CKD for specialist assessment (considering their wishes and comorbidities) if they have any of the following**](https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173)](https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-and-management-pdf-66143713055173)**:**  **• 5-year risk of needing renal replacement therapy of greater than 5% (measured using the 4-variable** [**Kidney Failure Risk Equation**](https://kidneyfailurerisk.co.uk/) **)**  **• ACR of 70 mg/mmol or more, unless known to be caused by diabetes and already appropriately treated**  **• ACR of more than 30 mg/mmol (ACR category A3), together with haematuria**  **• a sustained decrease in eGFR of 25% or more and a change in eGFR category within 12 months**  **• a sustained decrease in eGFR of 15 ml/min/1.73 m2 or more per year**  **• hypertension that remains poorly controlled (above the person's individual target) despite the use of at least 4 antihypertensive medicines at therapeutic doses**  **• known or suspected rare or genetic causes of CKD**  **• suspected renal artery stenosis.**  **•Patients with eGFR <30 ml/min/1.73 m2 will usually require referral; but with eGFR ≥30 ml/min/1.73 m2 referral will depend on other factors as above.** |
| normal or mildly increased | moderately increased | severely increased |  |
| <30mg/g or <3mg/mmol | 30-300mg/g or 3-30mg/mmol | >300mg/g or 30mg/mmol |  |
|  | | | | A1 | A2 | A3 |  |
| EGFR categories | G1 | normal or high | ≥90 | *1* if CKD | *1*  monitor | *2*  A&G/Refer |  |
|  | G2 | mildly decreased | 60-89 | *1* if CKD | *1*  monitor | *2*  A&G/Refer |  |
|  | G3a | mildly to moderately decreased | 45-59 | *1*  Monitor | *2*  monitor | *3*  refer |  |
|  | G3b | moderately decreased | 30-44 | *2*  Monitor | 3  monitor | *3*  refer |  |
|  | G4 | severely decreased | 15-29 | *3*  A&G/Refer | *3*  A&G/Refer | *4+*  refer |  |
|  | G5 | kidney failure | <15 | *4+*  refer | *4+*  refer | *4+*  refer |  |
| **A&G = Advice and Guidance or refer NB:** **G1A1 and G2A1 only classed as CKD if also have additional Markers of Kidney Disease e.g. renal stone disease.** | | | | | | |  |  |
|  | | | | | | |  |  |
| Patient Information  How to Look after your kidneys <https://www.kidneycareuk.org/order-or-download-booklets/ckd-health-check-look-after-your-kidneys-and-keep-yourself-well/>  Chronic Kidney Disease <https://www.kidneycareuk.org/order-or-download-booklets/chronic-kidney-disease/>  A healthy diet and lifestyle for kidneys <https://www.kidneycareuk.org/order-or-download-booklets/healthy-diet-and-lifestyle-your-kidneys/>  Medicines for chronic kidney disease <https://www.kidneycareuk.org/order-or-download-booklets/medicines-chronic-kidney-disease/>  Medicines for high blood pressure <https://www.kidneycareuk.org/order-or-download-booklets/medicines-high-blood-pressure/>  Diabetes and kidney disease <https://www.kidneycareuk.org/order-or-download-booklets/diabetes-and-kidney-disease/> | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 4 Key things in 4 months to Save Lives for Adults with CKD **(ideally do in every patient with eGFR<60 or UACR ≥ 3 mg/mmol)** | | | | | | | | | |
| Month 1 | Month 2 | | | | | Month 3 | | Consider at month 4 onwards | |
| **Maximum intensity RAS/ RAAS blockade and Optimise Lipids** | **Start SGLT2i**  **(Referring to ‘safe and effective use of SGLT2is’ guidance)** | | | | | **Optimise Blood Pressure and Other Cardiovascular Risk Factors** | | **Consider referral for Finerenone**  **(**[**see shared care guidance)**](https://www.swyapc.org/search-individual-drug/) | |
| Start ACE-inhibitor or ARB in the following populations:   1. Adults with hypertension and an ACR>30mg/mmol (category A3 or above) 2. Adults with diabetes and an ACR>3mg/mmol (category A2) 3. Adults without diabetes and ACR>70mg/mmol (also refer to nephrology)   Titrate to maximum tolerated licensed dose (*NICE, NG203*) Ideally do this within one month (see rapid titration protocol for RAAS blockade below)  Atorvastatin 20mg once daily should be offered as initial therapy for primary and secondary prevention and national guidelines followed for review and titration. Optimise lipid lowering therapies according to national lipid lowering guidance [NHS Accelerated Access Collaborative » Summary of national guidance for lipid management (england.nhs.uk)](https://www.england.nhs.uk/aac/publication/summary-of-national-guidance-for-lipid-management/) | **Person with Type 2 Diabetes**  Start Dapagliflozin 10mg once daily ensuring the person has an eGFR 25-75 mL/min/1.73m2 recognising that glycaemic benefits will be limited at an eGFR <45ml/min/1.73m2  **OR**  Start Empagliflozin 10mg once daily ensuring the person has an eGFR 20-90ml/min/1.73m2 recognising that glycaemic benefits will be limited at an eGFR<45ml/min/1.73m2 | **Person without Type 2 Diabetes** **(NB not for people living with T1DM unless under specialist care)**  Start Dapagliflozin 10mg once daily ensuring the person has:   1. an eGFR 25-75 mL/min/1.73m2 **and** 2. UACR of ≥22.6 mg/mmol, excluding people with polycystic kidney disease or on immunological therapy for renal disease who would not be suitable for SGLT2i therapy.   **OR**  Start Empagliflozin 10mg once daily ensuring the person has either:   1. An eGFR 20 ml/min/1.723m2 to less than 45ml/min/1.73m2 **OR** 2. An eGFR 45ml/min/1.73m2 -90ml/min/1.73m2 and UACR ≥ 22.6mg/mmol. | | | | Initiate further blood pressure agents to treat to target   * UACR < 70mg/mmol:   <130/80mmHg   * UACR>70mg/mmol:   Ideally <120/80mmHg taking into consideration frailty and co-morbidities.  **Caution in the elderly/frail – consider reviewing the targets**  Encourage home monitoring of Blood Pressure (NB targets are 5mmHg lower for HBPM)  In those who have had a cardiovascular event, ensure offered aspirin with appropriate gastric protection (in some cases a H2 receptor antagonist may be preferred e.g., if having electrolyte abnormalities or in the instance of acute interstitial nephritis (ANI). Famotidine is the H2 receptor antagonist of choice in this situation).  Aspirin may be considered for primary prevention in those at high cardiovascular risk. Initiation should be balanced with consideration of the increased bleeding risk, including thrombocytopathy with low eGFR.  In those with established CAD or PAD at high risk of ischaemic events ([see NICE](https://www.nice.org.uk/guidance/ta607/chapter/1-Recommendations)) consider 2.5mg bd rivaroxaban alongside aspirin. Only if eGFR>15ml/min. | | Only for people living with Type 2 Diabetes and who also has:   * stage 3 or 4 CKD (eGFR ≥25- <60ml/min/1.73m2) with albuminuria (UACR ≥3mg/mmol) * been optimised on standard care (RAAS blockade and SGLT2ihibitors)   Finerenone can only be initiated if serum potassium ≤4.8mmol/L or if serum potassium >4.8 to 5 mmol/L then initiation can be considered with additional monitoring in the first 4 weeks based on patient characteristics and potassium levels.  Initiate the lower dose of Finerenone 10mg if eGFR 25-59ml/min/1.73m2 | |
| *(NB: Agents are listed in alphabetical rather than preferential order)*  Follow the guidance in the document ‘Safe and Effective Use of SGLT2is’  \*We would not advocate switching SGLT2is so in those already established (including those on Canagliflozin) we would advise they continue and those already established on empagliflozin 25mg once daily should continue unless indicated to drop dose.  Specialist initiation only if history of: transplantation; on immunological therapy; polycystic kidney disease; haemodialysis. | | | | |
| Lifestyle advice – diet, exercise, weight management, smoking cessation | | | | | | | | | |
| **Rapid Titration Protocol for RAAS Blockade**  NO  Assess if patient suitable for rapid RAAS titration (unsuitable if low baseline blood pressure, people with significant co-morbidities, potassium level already near ULN)  If not consider reducing any other BP medications and where appropriate setting frailty targets for blood pressure  Check creatinine and potassium 1-2 weeks after initiation and recheck blood pressure.  Increase ACE inhibitor (or ARB if ACEi not tolerated) to maximum tolerated dose e.g., Ramipril 10mg od.  Start ACE inhibitor (or ARB if ACE I not tolerated) at half maximum dose e.g., Ramipril 5mg once daily   * Advise on [Sick Day Rules](https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2018/01/Think-Kidneys-Sick-Day-Guidance-2018.pdf) sick day rules. * Advise on good fluid intake 1-2L/day depending on size.   Consider a slower titration of RAAS blockade and consider a reduced dose at initiation  YES  Check creatinine and potassium 1-2 weeks after each dose titration and recheck blood pressure. | | |  | **Blood Results and Monitoring**  **ACE inhibitor and ARB**  ***eGFR and Serum Creatinine***  Accept a serum creatinine rise < 30% or eGFR fall of < 25% from baseline: after ACEi/ARB initiation or dose increase.  If renal function deterioration greater than stated above seek nephrologist advice (to exclude possible reno-vascular disease)  STOP ACEi/ARB if changes in creatinine/ eGFR exceed the above and no other causes of deteriorating renal function (e.g., dehydration, use of NSAIDs) is found.  ***Potassium (K+)***  If K+ >6.0 mmol/L -would need urgent repeat U&E (please follow local guidance and ideally this would be a same day repeat) and if 6.5 mmol/L or greater or if there are symptoms consistent with hyperkalaemia, you would usually send to A&E for repeat potassium and ECG. If K+ >6.0 mmol/L stop ACEi/ARB and start low potassium diet, a recommended patient information can be found: <https://www.kidney.org.uk/potassium>.  If K+ remains persistently ≥6.0mmol/L and because of this hyperkalaemia people are unable to take an optimised dose of RAAS inhibitor. consider referral for sodium zirconium cyclosilicate (for CKD stage 3b-5, not on dialysis only)  If K+ >5.5mmol/ stop MRAs (including Finerenone)  Aim to restart medications once K+ ≤ 5.5 mmol/L (note lower starting doses with Finerenone below)  If the patient has proteinuria or heart failure with reduced ejection fraction and would benefit from an ACEi/ARB seek nephrologist advice as introduction of furosemide, potassium binders or bicarbonate to facilitate reintroduction of these agents.  Concomitant use of ACEi/ARB with spironolactone and other potassium sparing diuretics requires close monitoring of potassium. The Think Kidneys campaign has a useful guidance which can be found [2020-statement-on-Changes-in-Kidney-Function-FINAL.pdf (thinkkidneys.nhs.uk)](https://www.thinkkidneys.nhs.uk/aki/wp-content/uploads/sites/2/2020/01/2020-statement-on-Changes-in-Kidney-Function-FINAL.pdf)  **Finerenone**  Serum potassium and eGFR must be remeasured 1-2 weeks after initiation or re-start of Finerenone treatment or after an increase in dose (note SPC recommends 4 weeks). Then to check at 4 weeks, if normal to then extend monitoring to 3 months and thereafter the serum potassium is monitored exactly as would be undertaken based on the individual’s long-term health conditions or acute health conditions that may arise (a minimum of every 12 months) ([see shared care guidelines](https://www.swyapc.org/search-individual-drug/)) | | | | | |
|  | | |  |  | | | Current Finerenone dose | | |
|  | | |  | 10mg | | 20mg |
|  | Current Serum Potassium | ≤4.8mmol/L | | Increase to 20mg once daily | | Continue 20mg once daily |
|  | >4.8-5.5mmol/L | | Continue 10mg once daily | | Continue 20mg once daily |
|  | >5.5mmol/L | | Withhold. Consider to Re-start at 10 mg once daily when serum potassium ≤ 5.0 mmol/L. | | Withhold. Consider to re-start at 10 mg once daily when serum potassium ≤ 5.0 mmol/L. |

Fluid overload (check decompensated HF)

Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019 Jun;105(12):904-910. doi: 10.1136/heartjnl-2018-314158. PMID: 31118203; PMCID: PMC6582720.

HFpEF

* Stop RAAS blockade as no prognostic benefit.
* MRA may offer symptomatic benefit.
* Stop RAAS blockade if not for prognostic benefit.
* May need IV fluids and repeat clinic/biochemical review.
* May temporarily withhold RAAS blockade even if for prognostic benefit (e.g., if symptomatic hypotension despite volume correction, moderate/severe hyperkalaemia, progressively worsening renal function)
* Stop RAAS blockade if not for prognostic benefit.
* May need IV fluids and repeat clinic/biochemical review.
* May temporarily withhold RAAS blockade even if for prognostic benefit (e.g., if symptomatic hypotension despite volume correction, moderate/severe hyperkalaemia, progressively worsening renal function)

HFrEF

Consider reducing/withholding RAAS blockade if:

* Symptomatic hypotension
* Moderate/severe hyperkalaemia
* Progressive worsening renal function

Patient with Heart Failure and established on RAAS Blockade unwell with AKI/worsening renal function.

Hypotension (as compared to usual BP) +/- hypovolaemia.

Infection (treat with antibiotics as per local guidance)